Intercept Not Changing NDA Refiling Plans After OCA Misses NASH Cirrhosis Endpoint

 
• By Joseph Haas
  
Failed experiment
Failure in cirrhotic NASH will not scuttle Intercept's overall plans in the disease • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D